- Financing round brings five new investors to Atonarp, including Japan Post 
  Investment Corporation and SBI Investment Co., Ltd. 

- Series C was oversubscribed as investor demand was driven by the company's 
  accelerating development progress of disruptive healthcare diagnostics 
  platform.

- Funding will be used primarily to support Atonarp's product prototyping and 
  commercialization in 2020 and beyond, as well as build on and reinforce the 
  company's technology platforms.

Atonarp, a hi-tech molecular diagnostics company, today announced that it has 
raised $33 million in an oversubscribed Series C funding round. This financing 
round has attracted five new investors including Japan Post Investment 
Corporation, SBI Investment Co., Ltd, and Northwestern Mutual Future Ventures 
as well as current investors, INCJ, Ltd, Innovative Venture Fund Investment 
Limited Partnership, and a major medical equipment manufacturing company. 

Photo - https://mma.prnewswire.com/media/964547/Smart_Pass_Spectrometer.jpg 
Logo - https://mma.prnewswire.com/media/597038/Atonarp_CMYK_Logo.jpg 

Since early 2014, Atonarp has raised more than $61 million in three rounds of 
equity financing in pursuit of its vision of ushering in the next generation of 
process monitoring and healthcare diagnostics through its innovative AI-based 
platforms of mass spectrometry and optical spectroscopy. The latter is geared 
to deliver pain-free point-of-care blood testing with lab-quality accuracy but 
with real-time actionable data. These unparalleled advantages are also expected 
to bring about cost savings to patients and healthcare providers. The Series C 
funding will grow the company's balance sheet and support ongoing product 
prototyping and commercialization into the healthcare market.

"Atonarp has continued to execute at a fast pace towards our goal of disrupting 
the old healthcare diagnostics model that is time-consuming, painful and 
costly," said Prakash Murthy, Chief Executive Officer of Atonarp. "With our 
recent innovative engineering progress, we are well-positioned to meet our 
product roadmap deliverables in 2020. Both the general population and 
healthcare providers are ready for this revolutionized healthcare experience - 
especially when it is priced competitively. We are honored to welcome these 
long-term investors to the Atonarp community as we look forward to what's ahead 
for the company in terms of line of products and services that we are 
feverishly executing on." 

"As a growth investment fund, SBI Investment is looking for opportunities to 
invest in fast growing sector leaders whose potential to use technology will 
enhance the customer experience of large populations," said Yusuke Matsumoto, 
Deputy General Manager, Investment Department of SBI Investment. "Not only has 
Atonarp proved this is possible with its innovative technology platform, but 
the artificial intelligence in tandem with the data analytics model that they 
are building has the potential to produce personalized health portfolios for 
millions of people and disrupt medicine - and healthcare - as we have come to 
know and accept it."

Yuichi Kawakami, Partner of Innovative Venture Fund, NEC Capital Solutions Ltd, 
said, "Atonarp differentiated mass spectrometry platform is solving 
long-standing issues in the intricate production processes of the 
pharmaceutical and semiconductor sectors.  In healthcare sector, Atonarp is 
poised to deliver high quality, integrated and affordable lab-type diagnostics 
to the population at large. We are excited to support Atonarp through this next 
phase of the company's growth."

Mikihide Katsumata, President and COO of INCJ, Ltd. who led this financing 
round as a repeat investor, said that "Atonarp is the healthcare diagnostics 
entrant with the best chance of disrupting the conventional status quo of the 
medical lab testing industry. This financing round positions Atonarp well to 
capitalize on its transformational engineering approach to medical diagnostics 
in order to revolutionize patient experience through a smart personalized 
healthcare business model empowered by real-time actionable data." 

About Atonarp
Atonarp is a Molecular Diagnostics company. Through its partners in the tech 
world, Atonarp is reshaping how sensing and diagnostics devices are applied to 
generate real-time actionable data and achieve drastically better outcomes in 
industrial processes and healthcare. Learn more at www.atonarp.com.

Contact: 
Katsuhiko Nakazawa, Atonarp Inc.
Tokyo Office: +81-3-6435-6234
Tokyo Mobile: +81-80-4124-8333 (Japan)
Katsuhiko.nakazawa@atonarp.com

SOURCE: Atonarp Inc.